Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited ... 20%+ free cash flow yield. New leadership has focused ...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE ... 4 times earnings and with a 20%+ free cash flow yield. New ...
AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research ... Cohen, Teva Corporate Communications: +31 6 2008 2545 Notes to Editors: About Teva Pharmaceuticals Teva Pharmaceutical Industries ...
will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug ...
a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr ...
The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...
Headquartered in New York, BMS today has approximately ... collaboration with Nissan Chemical Industries and Teijin Pharma for the development and commercialisation of an oral atrial-selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback